# Sermorelin Dosage in the Research Literature: Doses, Routes, Handling

> Sermorelin dosage as documented in research: the pediatric efficacy dose, the older-men aging-study doses, diagnostic IV testing, and reconstitution handling — research context only.

What was administered, to which population, by which route — charted from the studies, not prescribed for anyone.

## Start here

This page maps the sermorelin dosage figures that appear in published studies — and only as study facts. It does not tell anyone what to take. Doses are reported the way researchers reported them: a specific amount, given to a specific group of people, by a specific route (usually an injection under the skin). The most-cited numbers come from a children's growth study, an aging study in older men, and pharmacokinetic testing. Read them as a record of how the science was run, with the units and the population attached to every figure.

## Research doses on record

The sermorelin dosage figures in the literature cluster by study type. In the pediatric growth-hormone-deficiency efficacy study, GHRH(1-29) was administered subcutaneously at 30 mcg/kg/day at bedtime [1]. In aging research, healthy older men received 0.5 mg and 1 mg subcutaneously twice daily for 14 days [2]. In pharmacokinetic work, intravenous doses of 0.25-2 mcg/kg elicited growth hormone release in healthy men, with maximal release at 1-2 mcg/kg [3]. Diagnostically, a single intravenous bolus (commonly around 1 mcg/kg) was historically used to test pituitary growth hormone reserve.

Each of these is a study parameter, not a recommendation. The doses differ because the purposes differ — a daily growth-promoting regimen in children, a short reversal study in older men, an acute provocation test of the pituitary. None of them is offered here as guidance for any individual.

## Why bedtime dosing appears in the studies

Several studies timed administration to the evening, and the reason is physiologic. The largest natural growth hormone pulse occurs during slow-wave sleep, so dosing before bedtime aligns the stimulus with the body's own rhythm. The pediatric efficacy study administered GHRH(1-29) subcutaneously at bedtime [1], and the GHRH-analog cognition trial dosed before bedtime [6]. This reflects how the trials were designed to work with endogenous pulsatility — it is not a dosing instruction for any individual.

## Handling, reconstitution, and stability

Lyophilized sermorelin acetate is reconstituted with sterile diluent; once reconstituted, it is typically refrigerated, because aqueous peptide solutions are susceptible to degradation, which is why GHRH(1-29) is supplied as a freeze-dried powder [3]. Compounded preparations are prepared under USP <797> sterile-compounding standards. Route choice follows the pharmacokinetics: subcutaneous injection is primary, intravenous appears in diagnostic and PK studies, and intranasal delivery was tested historically but achieved only about 3-5% bioavailability [3]. This describes laboratory and compounding handling, not self-administration guidance.

## Does sermorelin need to be refrigerated?

In the research literature, sermorelin acetate is supplied as a lyophilized (freeze-dried) powder because aqueous peptide solutions are prone to degradation. It is reconstituted with a sterile diluent, and once reconstituted it is typically refrigerated [3]. Compounded preparations are made under USP <797> sterile-compounding standards. This describes laboratory and compounding handling, not self-administration guidance.

---

The sermorelin record charted like an expedition — the GHRH(1-29) signal followed from pituitary to IGF-1, each figure carried back to its study, the body-composition data marked as tesamorelin where it belongs, and the stretch where the adult anti-aging evidence runs out left openly unmapped; no clinic behind the compass and nothing here prescribed, dispensed, or sold.